Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression

NCT00275054 is registered in ClinicalTrials.gov with German CLL Study Group as lead sponsor.

NCT NCT00275054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00275054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression
Lead sponsor
German CLL Study Group
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
June 30, 2015
Enrollment
825 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia